UPDATE: Jefferies Raises PT to $65 on CME Group on Long-Term Outlook
Jefferies reiterated its Buy rating on CME Group (NASDAQ: CME) and raised its price target from $60 to $65.
Jefferies noted, "Last week we spent several days with the management team of CME Group. The focus of the meetings centered around OTC clearing and execution initiatives and the globalization of CME's products, all of which represent potential offsets to the current lackluster environment for trading. On a longer-term basis we see several structural changes that should drive accelerating growth at CME."
CME Group closed at $57.29 on Friday.
Latest Ratings for CME
|May 2016||Buckingham Research||Initiates Coverage on||Buy|
|Apr 2016||Keefe Bruyette & Woods||Maintains||Market Perform|
|Mar 2016||JP Morgan||Maintains||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.